Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Arthropod Borne Dis ; 8(1): 53-9, 2014.
Article in English | MEDLINE | ID: mdl-25629065

ABSTRACT

BACKGROUND: The brown-banded cockroach, Supella longipalpa is known as a carrier of pathogenic bacteria in urban environments, but its role is not well documented regarding the carriage of antibiotic-resistant pathogenic bacteria in Iran. The aim of this study was to determine the resistance bacteria isolated from the brown-banded cockroach in Ahvaz, south west of Iran. METHODS: Totally 39 cockroaches were collected from kitchen area of houses and identified. All specimens were cultured to isolate the bacterial agents on blood agar and MacConky agar media. The microorganisms were identified using necessary differential and biochemical tests. Antimicrobial susceptibility tests were performed for isolated organisms by Kirby-Bauer's disk diffusion according to NCLI guideline, using 18 antibiotics. RESULTS: From the 39 collected S. langipalpa, 179 bacterial agents were isolated, 92 of alimentary ducts and 87 of external body surfaces. Isolated bacteria from cockroaches were identified as Enterobacter spp., Klebsiella spp., Citrobacter spp., Escherichia coli, Salmonella spp., Proteus spp., coagulase negative staphylococci, Serratia marcescens, Staphylococcus aureus, and Bacillus species. The pattern resistance rates were determined for gram negative bacilli and gram positive cocci regarding 18 antibiotics. CONCLUSION: The brown-banded cockroach can be involved in the spread of drug resistant bacteria and increases the possibility of contacting human environment to drug resistant bacteria. Therefore, the potential of removing this insect should be improved. This is the first original report of drug resistant bacteria isolated from the brown-banded cockroach of Iran.

2.
Jundishapur J Nat Pharm Prod ; 7(1): 17-21, 2012.
Article in English | MEDLINE | ID: mdl-24624146

ABSTRACT

BACKGROUND: Previous studies have shown that shallomin, one of the active constituents of Persian shallot, has a broad range of antimicrobial properties. OBJECTIVES: The safety of shallomin must be established before it can be used in clinical applications. Therefore, the aim of the present study was to evaluate the acute toxic effects of shallomin and to estimate its lethal dose low (LDLo) value. MATERIALS AND METHODS: TWO SERIES OF EXPERIMENTS WERE PERFORMED: In the first series, we used functional testing to assess the acute toxic effects of shallomin on the blood, liver, and kidney and examined histopathological changes in the liver, kidney, lung, and heart, following 7 days of daily intraperitoneal administration of 3 standard doses (10, 20, and 30 µg/g body weight of mice). In the second series, the LDLo value was estimated by determining daily mortality in mice after 7-day administration of escalating doses of shallomin (10 to 240 µg/g body weight of mice). RESULTS: The results showed that shallomin (at the anticipated in vivo doses), unlike the placebo (ethanol), did not produce any adverse effects on the tested organs. The LDLo value was observed to be 160 µg/g body weight; this value is 8- to 32-times the anticipated in vivo dose that produces antimicrobial effects under in vitro conditions against various pathogenic organisms. CONCLUSIONS: In conclusion, the results of the present study show that shallomin is a relatively safe agent, although its use needs to be carefully monitored. Further in vivo chronic toxicity tests need to be performed to establish the therapeutic potential of shallomin as an antimicrobial agent.

3.
Med Mycol ; 46(1): 17-21, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17885954

ABSTRACT

The aim of the present study was to investigate the incidence of fungal and bacterial contaminations of in-use eye drop products in the teaching department of ophthalmology, Imam Khomeini Hospital, Ahvaz. Two hundred and eighty seven eye drop bottles were randomly collected at the end of day 1, day 2, day 3, day 4 and day 7 of use. The eye drop residues, swabs from internal caps and droppers were inoculated onto MacConkey agar, blood agar and Sabouraud's dextrose agar. The identification of the recovered organisms was accomplished using standard microbial identification techniques. The incidence of microbial contamination of in-use eye drop products was 17.8%, with the highest rate (24.6%) and the lowest rate (9.0%) noted with day 1 and day 3 samples, respectively. The most contaminated part of the eye drop products was the caps (45.9%) followed by droppers (41.0%) and residual contents (13.1%). Considering mendicants contents, those with pilocarpine (41.7%) had the highest rate of contamination followed by atropine (31.8%), tropicamide (28.6%) and betamethasone (23.3%). Our study revealed the potential risk of contamination of in-use eye drop products in hospitals, but we did not find a direct relationship between usage duration and contamination rate.


Subject(s)
Bacteria/isolation & purification , Drug Contamination , Fungi/isolation & purification , Ophthalmic Solutions/chemistry , Drug Packaging/standards , Drug Storage , Humans , Iran , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...